GSK says tests show Vir antibody drug works against Omicron


A GlaxoSmithKline (GSK) brand is seen on the GSK analysis centre in Stevenage, Britain November 26, 2019. Picture: Reuters

GlaxoSmithKline on Thursday stated {that a} pre-clinical evaluation of the antibody-based COVID-19 remedy it’s growing with US companion Vir has indicated that the drug additionally works in opposition to the brand new Omicron variant.

Additional assessments shall be carried out on the sotrovimab remedy to agency up the outcomes, GSK stated in an announcement.

Britain’s drug regulator on Thursday, in the meantime authorized GSK (GSK.L) and Vir Biotechnology’s (VIR.O) antibody primarily based COVID-19 remedy, Xevudy, for individuals with mild-to-moderate COVID-19 who’re at excessive danger of growing extreme illness.